Explaining the Relationships Between Age, Endocrine Therapy Persistence, and Risk of Recurrence in Hormone Receptor–Positive Early Breast Cancer: A Nationwide Cohort Study
The survival benefit that could be achieved with strict ET persistence in women 34 years and younger with HR-positive eBC highlights the need for tailored strategies to improve ET persistence in this population.
Authors
- Anne‐Sophie Hamy (ORCID: https://orcid.org/0000-0003-4430-3022)
- Fabien Reyal (ORCID: https://orcid.org/0000-0002-2318-3589)
- Floriane Jochum (ORCID: https://orcid.org/0000-0001-5009-3936)
- Paul Gougis (ORCID: https://orcid.org/0000-0003-3064-7043)
- Sophie Houzard (ORCID: https://orcid.org/0000-0002-0820-5743)
- Florence Coussy (ORCID: https://orcid.org/0000-0002-6443-8883)
- Élise Dumas (ORCID: https://orcid.org/0000-0002-7877-719X)
- Christine Le Bihan-Benjamin (ORCID: https://orcid.org/0000-0002-1868-9358)
- Alena Majdling (ORCID: https://orcid.org/0000-0001-9770-700X)
- Mats Julius Stensrud (ORCID: https://orcid.org/0000-0001-9641-1936)
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Immunité et Cancer (FR)
- Hôpital René Huguenin (FR)
- Institut National du Cancer (FR)
- Institut Jean Godinot (FR)
- École Polytechnique Fédérale de Lausanne (CH)
- Université de Strasbourg (FR)
- Institut Curie (FR)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1200/jco.24.01131
- Citations
- 10
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 18.17